An EU-funded study aims to restore the faith in of the use of gene therapy for treatment of primary immune deficiencies (PIDs). The CELL-PID project utilises genetically modified haematopoietic stem cells (HSCs) as a cell-based therapy for building a healthy immune system in patients with PIDs.
Further information: cordis.europa.eu